Are Biosimilars the Road to Certain Success or High Risk Venture?
Discover key global trends in the ambiguous biosimilars market during Frost & Sullivan’s complimentary webinar
WHEN: 6 pm BST on Thursday, 17 October 2013
LOCATION: Online, with free registration
SPEAKER: Frost & Sullivan Life Sciences Senior Industry Analyst Deborah Toscano
The biosimilars market is on the verge of transitioning from a state of infancy to an entrenched facet of healthcare. Numerous biosimilars, or follow-on biologics, have been successfully launched in many countries outside the US. Lower cost biosimilar versions of more complex biologic therapies, such as monoclonal antibodies, are now eagerly awaited and expected to significantly affect healthcare costs, particularly in the US, the largest market for biotechnology. However, residual uncertainties surrounding approval and commercial uptake could considerably influence the true potential of this market.
Attend this webinar to:
· Discover the issues around regulatory and payer acceptance of biosimilars in the US
· Learn how biosimilars are forecast to penetrate various biopharmaceutical segments and therapeutic areas
· Understand the potential risks and rewards of this market
· Gain insight into the competitive environment and potential US market leaders
· Identify the key factors with potential to impact the uptake of biosimilars.
This briefing will benefit biopharmaceutical industry market participants, investors, pharmacy benefit managers, as well as physicians and other healthcare community members who desire an in-depth analysis of the biosimilars market.
Supporting Quote
“Biosimilars has been one of the hottest pharma and biotech topics for several years now, and one fraught with much uncertainty, particularly the US market,” says Life Sciences Senior Industry Analyst Deborah Toscano. “Availability of follow-on versions of blockbuster monoclonal antibody therapies facing looming patent expiration, such as Humira and Erbitux, are anticipated to make a significant dent in healthcare spend. However, important differences between the biosimilars market and that of conventional generics make the accuracy of such predictions difficult, if not impossible.”
Supporting Resources
For more information about Frost & Sullivan’s Life Sciences practice, please visit: www.lifesciences.frost.com
Registration
• To attend the briefing, email [email protected] your full name, job title, company name, company telephone number, company email address and website, city, state and country.
• Receive a recorded version of the briefing anytime by submitting the aforementioned contact details.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance